Canadian preference and trends survey results for anti-VEGF treatment of macular edema.
Department of Ophthalmology, University of Alberta, Edmonton, Alta.
Jaspreet S
JS
Rayat
Department of Ophthalmology, University of Alberta, Edmonton, Alta.
Parampal S
PS
Grewal
Department of Ophthalmology, Memorial University, St. John's, Nfld.
James
J
Whelan
Department of Ophthalmology, University of Alberta, Edmonton, Alta.
Matthew T S
MT
Tennant
Herzig Eye Institute, Toronto, Ont.. Electronic address: netan.choudhry@gmail.com.
Netan
N
Choudhry
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use; D002170:Canada; D003930:Diabetic Retinopathy / Q000188:drug therapy; D004363:Drug Utilization / Q000639:trends*; D019538:Health Care Surveys; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy*; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D000069579:Ranibizumab / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012170:Retinal Vein Occlusion / Q000188:drug therapy; D011795:Surveys and Questionnaires; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D057135:Wet Macular Degeneration / Q000188:drug therapy
D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab